Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 3/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.45 |
| ▸ | SCN2B | O60939 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408229 | 0.84 | SCN9A (0.54) | SCN9ASCN5AKAT6A | |
| SCHEMBL7987664 | 0.80 | FLT1 (0.65) | FLT1FLT4KDRKCNMA1SCN9A | |
| SCHEMBL2404683 | 0.78 | BCL2L1 (0.43) | FLT1FLT4KDRBCL2L1MCL1 | |
| SCHEMBL2406313 | 0.78 | RXRA (0.58) | NPC1LMNARAB9AMAP4K4SERPINE1 | |
| SCHEMBL2408036 | 0.75 | SCN9A (0.46) | BCL2L1MCL1SCN9AMAP4K4KAT6A | |
| SCHEMBL29383897 | 0.75 | PTGER1 (0.47) | KCNMA1NPC1LMNARAB9ASERPINE1 | |
| Lithium Ion SCHEMBL29383941 | 0.75 | PTGER1 (0.45) | KCNMA1NPC1LMNARAB9ASERPINE1 | |
| Potassium Ion SCHEMBL29383367 | 0.75 | PTGER1 (0.45) | KCNMA1NPC1LMNARAB9ASERPINE1 | |
| SCHEMBL364563 | 0.73 | SCN9A (0.59) | FLT1FLT4KDRBCL2L1MCL1 | |
| SCHEMBL22866930 | 0.73 | SLC7A5 (0.41) | KCNMA1NPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | claimed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | claimed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | claimed |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2015-04-02 | — | — | US | disclosed |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC. | 2011-09-01 | — | — | US | disclosed |
| US-7790704-B2 | Thrombopoietin mimetics | GlaxoSmithKline, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7674887-B2 | Thrombopoietin mimetics | GLAXOSMITHKLINE LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-7648971-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20090176973-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2009-07-09 | — | — | US | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2007-08-02 | — | — | US | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-7160870-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | FLT1 16/4885FLT4 63/4885KDR 64/4885 |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | FLT1 16/4885FLT4 63/4885KDR 64/4885 |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | FLT1 16/4885FLT4 63/4885KDR 64/4885 |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | FLT1 16/4885FLT4 63/4885KDR 64/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | FLT1 16/4885FLT4 63/4885KDR 64/4885 |
| US-20090176973-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | FLT1 16/4885FLT4 63/4885KDR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.